Endocrine Abstracts

Prolactin (PRL) exerts independent hypertrophic effects on prostate in in vivo and in vitro experimental models, and prostatic PRL receptors are known to activate cell proliferation pathways such as MAPK and STAT. Nevertheless, in men with hyperprolactinemia the risk of prostate cancer has been found reduced suggesting a role of concomitant hypogonadism. Chronic cabergoline treatment generally normalizes PRL treatment and improves gonadal function. The curren...